BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 19204576)

  • 1. Angiogenic markers show high prognostic impact on survival in marginally operable non-small cell lung cancer patients treated with adjuvant radiotherapy.
    Andersen S; Donnem T; Al-Saad S; Al-Shibli K; Busund LT; Bremnes RM
    J Thorac Oncol; 2009 Apr; 4(4):463-71. PubMed ID: 19204576
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inverse prognostic impact of angiogenic marker expression in tumor cells versus stromal cells in non small cell lung cancer.
    Donnem T; Al-Saad S; Al-Shibli K; Delghandi MP; Persson M; Nilsen MN; Busund LT; Bremnes RM
    Clin Cancer Res; 2007 Nov; 13(22 Pt 1):6649-57. PubMed ID: 18006765
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic impact of fibroblast growth factor 2 in non-small cell lung cancer: coexpression with VEGFR-3 and PDGF-B predicts poor survival.
    Donnem T; Al-Shibli K; Al-Saad S; Busund LT; Bremnes RM
    J Thorac Oncol; 2009 May; 4(5):578-85. PubMed ID: 19318994
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CD4/CD8 co-expression shows independent prognostic impact in resected non-small cell lung cancer patients treated with adjuvant radiotherapy.
    Hald SM; Bremnes RM; Al-Shibli K; Al-Saad S; Andersen S; Stenvold H; Busund LT; Donnem T
    Lung Cancer; 2013 May; 80(2):209-15. PubMed ID: 23384671
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Basic fibroblast growth factor (bFGF) and vascular endothelial growth factor (VEGF) levels, as prognostic indicators in NSCLC.
    Iwasaki A; Kuwahara M; Yoshinaga Y; Shirakusa T
    Eur J Cardiothorac Surg; 2004 Mar; 25(3):443-8. PubMed ID: 15019676
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic impact of platelet-derived growth factors in non-small cell lung cancer tumor and stromal cells.
    Donnem T; Al-Saad S; Al-Shibli K; Andersen S; Busund LT; Bremnes RM
    J Thorac Oncol; 2008 Sep; 3(9):963-70. PubMed ID: 18758297
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fibroblast growth factor 2--a predictor of outcome for patients irradiated for stage II-III non-small-cell lung cancer.
    Rades D; Setter C; Dahl O; Schild SE; Noack F
    Int J Radiat Oncol Biol Phys; 2012 Jan; 82(1):442-7. PubMed ID: 20950963
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High expression of the transcriptional co-activator p300 predicts poor survival in resectable non-small cell lung cancers.
    Hou X; Li Y; Luo RZ; Fu JH; He JH; Zhang LJ; Yang HX
    Eur J Surg Oncol; 2012 Jun; 38(6):523-30. PubMed ID: 22440742
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Angiogenesis in non-small cell lung cancer: the prognostic impact of neoangiogenesis and the cytokines VEGF and bFGF in tumours and blood.
    Bremnes RM; Camps C; Sirera R
    Lung Cancer; 2006 Feb; 51(2):143-58. PubMed ID: 16360975
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The prognostic role of progesterone receptor expression in non-small cell lung cancer patients: Gender-related impacts and correlation with disease-specific survival.
    Skjefstad K; Richardsen E; Donnem T; Andersen S; Kiselev Y; Grindstad T; Hald SM; Al-Shibli K; Bremnes RM; Busund LT; Al-Saad S
    Steroids; 2015 Jun; 98():29-36. PubMed ID: 25668612
    [TBL] [Abstract][Full Text] [Related]  

  • 11. VEGF-A and VEGFR-3 correlate with nodal status in operable non-small cell lung cancer: inverse correlation between expression in tumor and stromal cells.
    Donnem T; Al-Shibli K; Al-Saad S; Delghandi MP; Busund LT; Bremnes RM
    Lung Cancer; 2009 Feb; 63(2):277-83. PubMed ID: 18599153
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association of immunoreactive hepatocyte growth factor with poor survival in resectable non-small cell lung cancer.
    Siegfried JM; Weissfeld LA; Singh-Kaw P; Weyant RJ; Testa JR; Landreneau RJ
    Cancer Res; 1997 Feb; 57(3):433-9. PubMed ID: 9012470
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Total cyclooxygenase-2 mRNA levels correlate with vascular endothelial growth factor mRNA levels, tumor angiogenesis and prognosis in non-small cell lung cancer patients.
    Yuan A; Yu CJ; Shun CT; Luh KT; Kuo SH; Lee YC; Yang PC
    Int J Cancer; 2005 Jul; 115(4):545-55. PubMed ID: 15704107
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical significance of vascular endothelial growth factor C and vascular endothelial growth factor receptor 3 in patients with nonsmall cell lung carcinoma.
    Arinaga M; Noguchi T; Takeno S; Chujo M; Miura T; Uchida Y
    Cancer; 2003 Jan; 97(2):457-64. PubMed ID: 12518370
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vascular endothelial growth factor immunostaining correlates with postoperative relapse and survival in non-small cell lung cancer.
    Yilmaz A; Ernam D; Unsal E; Demirag F; Atikcan S; Taştepe I
    Arch Med Res; 2007 Oct; 38(7):764-8. PubMed ID: 17845896
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combination of low vascular endothelial growth factor A (VEGF-A)/VEGF receptor 2 expression and high lymphocyte infiltration is a strong and independent favorable prognostic factor in patients with nonsmall cell lung cancer.
    Donnem T; Al-Shibli K; Andersen S; Al-Saad S; Busund LT; Bremnes RM
    Cancer; 2010 Sep; 116(18):4318-25. PubMed ID: 20549821
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vascular endothelial growth factor A and vascular endothelial growth factor receptor 2 expression in non-small cell lung cancer patients: relation to prognosis.
    Bonnesen B; Pappot H; Holmstav J; Skov BG
    Lung Cancer; 2009 Dec; 66(3):314-8. PubMed ID: 19324448
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Vascular endothelial growth factor/KDR activated microvessel density versus CD31 standard microvessel density in non-small cell lung cancer.
    Koukourakis MI; Giatromanolaki A; Thorpe PE; Brekken RA; Sivridis E; Kakolyris S; Georgoulias V; Gatter KC; Harris AL
    Cancer Res; 2000 Jun; 60(11):3088-95. PubMed ID: 10850461
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The emerging outcome of postoperative radiotherapy for stage IIIA(N2) non-small cell lung cancer patients: based on the three-dimensional conformal radiotherapy technique and institutional standard clinical target volume.
    Feng W; Zhang Q; Fu XL; Cai XW; Zhu ZF; Yang HJ; Xiang JQ; Zhang YW; Chen HQ
    BMC Cancer; 2015 May; 15():348. PubMed ID: 25934006
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vascular endothelial growth factor, platelet-derived endothelial cell growth factor and angiogenesis in non-small-cell lung cancer.
    O'Byrne KJ; Koukourakis MI; Giatromanolaki A; Cox G; Turley H; Steward WP; Gatter K; Harris AL
    Br J Cancer; 2000 Apr; 82(8):1427-32. PubMed ID: 10780522
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.